LPGO Stock Financial Analysis - Lipigon Pharmaceuticals AB (publ) (OM) Stock

Overview

Lipigon Pharmaceuticals AB, based in Sweden, operates within the biotechnology sector, primarily focusing on developing gene therapies for lipid-related disorders. The company leverages its expertise in lipid biology to pioneer treatments for diseases such as hyperlipidemia and lipodystrophy. A noteworthy project includes their collaboration with CombiGene to co-develop gene therapies designed to combat lipodystrophy, a venture that demonstrates Lipigon’s commitment to addressing complex lipid disorders through innovative genetic solutions. This strategic focus not only highlights their dedication to addressing significant unmet medical needs but also positions Lipigon as a key player in the advancement of lipid science within the pharmaceuticals industry.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is 1.32 MM.
The operating income for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -36.30 MM.
The net income for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -35.29 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	1.32	-36.30	-35.29
2025-03-31	10.29	-28.32	-27.00
2024-12-31	10.29	-26.93	-25.26
2024-09-30	8.97	-22.95	-22.11
2024-06-30	9.33	-21.88	-20.25
2024-03-31	16.41	-14.29	-12.71
2023-12-31	16.41	-13.45	-12.13
2023-09-30	16.41	-14.76	-13.77
2023-06-30	16.05	-15.96	-15.74
2022-12-31		-38.13	-37.70
2022-09-30	0.13	-43.65	-42.93
2022-06-30	0.73	-48.37	-47.52
2022-03-31	1.42	-46.08	-45.24
2021-12-31	2.21	-42.16	-41.11
2021-09-30	2.90	-32.09	-31.49
2021-06-30	4.34	-21.14	-20.89
2021-03-31	4.10	-12.22	-12.05
2020-12-31	4.01	-7.82	-8.07

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31
2024-09-30	-0.21	-0.21
2024-06-30	-0.19	-0.19
2024-03-31	-0.14	-0.15
2023-12-31	-0.19
2023-09-30	-0.23	-0.23
2023-06-30	-0.49	-0.49
2022-12-31	-2.57
2022-09-30	-3.56	-3.56
2022-06-30	-4.88	-4.88
2022-03-31	-4.65	-4.65
2021-12-31	-4.56
2021-09-30	-4.08	-4.08
2021-06-30	-3.27	-3.27
2021-03-31	-2.39	-2.39
2020-12-31	-1.83	-1.83

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -28.76 MM.
The cash from investing activities for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is 0.00 MM.
The cash from financing activities for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is 34.23 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-28.76	0.00	34.23
2025-03-31	-25.92	-0.23	5.89
2024-12-31	-24.78	-0.23	4.58
2024-09-30	-32.33	-0.23	17.86
2024-06-30	-15.65	-0.23	17.91
2024-03-31	-17.53		37.09
2023-12-31	-14.32		36.70
2023-09-30	-13.79		23.42
2023-06-30	-28.47		42.03
2022-12-31	-37.47		18.61
2022-09-30	-42.58	0.00	18.61
2022-06-30	-46.88	0.00	0.00
2022-03-31	-41.97	0.00	0.00
2021-12-31	-35.30	-0.12	51.09
2021-09-30	-29.79	1.18	54.09
2021-06-30	-18.46	-0.32	54.09
2021-03-31	-13.92	1.15	69.97
2020-12-31	-8.62	1.25	18.88

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/e for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -0.59.
The p/book for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is 0.55.
The p/tbv for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is 0.55.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30	-0.59	0.55	0.55
2025-03-31	-0.87	1.04	1.04
2024-12-31	-0.76	0.90	0.90
2024-09-30	-2.04	1.64	1.64
2024-06-30	-2.62	1.55	1.55
2024-03-31	-1.53	0.65	0.65
2023-12-31	-0.85	0.52	0.52
2023-09-30	-0.74	0.42	0.42
2023-06-30	-1.41	0.81	0.81
2022-12-31	-0.07	0.23	0.23
2022-09-30	-0.13	0.43	0.43
2022-06-30	-0.06	0.13	0.13
2022-03-31	-0.06	0.19	0.19
2021-12-31	-0.05	0.04	0.04
2021-09-30	-0.05	0.04	0.04
2021-06-30	-0.07	0.03	0.03
2021-03-31	-0.12	0.02	0.02
2020-12-31

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -2.22.
The ebit (3y)/ev for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -1.72.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	-2.22	-1.72
2025-03-31	-2.63	-2.79
2024-12-31	-3.71	-4.40
2024-09-30	-0.92	-1.17
2024-06-30	-1.37	-3.37
2024-03-31	0.90	2.26
2023-12-31	1.02	2.18
2023-09-30	2.82	5.02
2023-06-30	-3.19	-5.68
2022-12-31	3.40	1.97
2022-09-30	4.32	2.66
2022-06-30	46.90	24.15
2022-03-31	3.23	1.48
2021-12-31	0.82	0.27
2021-09-30	0.82	0.35
2021-06-30	0.43	0.20
2021-03-31	0.21	0.12
2020-12-31	0.00	0.00

Management Effectiveness

The roa for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -0.89.
The roe for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -1.40.
The roic for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -0.92.
The croic for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -0.69.
The ocroic for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -0.89.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.89	-1.40	-0.92	-0.69	-0.89
2025-03-31	-0.86	-1.26	-1.20	-0.78	-1.75
2024-12-31	-0.82	-0.97	-1.20	-0.78	-1.75
2024-09-30	-0.82	-0.97	-0.80	0.09	-0.62
2024-06-30	-2.66		-0.59	0.92	-0.82
2024-03-31	-1.12	-3.13	-0.43	0.78	-0.50
2023-12-31	-0.82	-1.05	-0.61	0.42	-0.61
2023-09-30	-0.49	-0.78	-0.57	0.49	-1.03
2023-06-30	-1.18	-1.87	-0.57	0.49	-1.03
2022-12-31	-1.04	-1.15	-3.29	-1.84	-3.26
2022-09-30	-1.15	-1.15	-3.29	-1.84	-3.26
2022-06-30	-0.85	-0.97	-2.36	-2.31	-2.33
2022-03-31	-0.67	-0.76	-3.24	-3.03	-3.01
2021-12-31			-0.84	0.69	-0.80
2021-09-30		-14.52	-0.84	0.69	-0.38
2021-06-30	-6.51	-9.63	-0.43	0.72	-0.38
2021-03-31	-3.75	-5.55	-0.20	0.97	-0.24
2020-12-31

Gross Margins

The gross margin for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -1.83.
The net margin for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -2.62.
The operating margin for Lipigon Pharmaceuticals AB (publ) as of 30 June 2025 is -2.75.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	-1.83	-2.62	-2.75
2025-03-31	-1.65	-2.46	-2.56
2024-12-31	-1.65	-2.46	-2.56
2024-09-30	-1.49	-2.17	-2.35
2024-06-30	-0.35	-0.76	-0.84
2024-03-31	-0.31	-0.74	-0.82
2023-12-31	-0.43	-0.84	-0.90
2023-09-30	-0.53	-0.98	-0.99
2023-06-30	-0.53	-0.98	-0.99
2022-12-31	-289.81	-332.78	-338.33
2022-09-30	-57.50	-332.78	-338.33
2022-06-30	-27.77	-64.83	-65.98
2022-03-31	-16.30	-31.93	-32.52
2021-12-31	-9.00	-10.84	-10.83
2021-09-30	-3.68	-10.84	-10.83
2021-06-30	-3.68	-4.81	-4.75
2021-03-31	-2.07	-2.94	-2.98
2020-12-31